Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Pharma & Drugs
Share your love
Treatment of Intraocular Melanoma | OBN
Melanoma of the uveal tract (iris, ciliary body, and choroid), though rare, is the most common primary intraocular malignancy in adults. The mean age-adjusted incidence of uveal melanoma in the United States is approximately 4.3 new cases per million people,…
4DMT Reports Positive Interim Data for Wet AMD Treatment
4D Molecular Therapeutics (4DMT) announced positive interim data from the Phase 2 PRISM clinical trial, marking a significant stride in the treatment of wet age-related macular degeneration (wet AMD). Arshad M. Khanani, MD, MA, FASRS, presented the data at the…
Mireca Medicines Gets $1M Boost for Retinal Disease Treatment
Mireca Medicines has been awarded a $989,000 ‘Translational Research Acceleration Program Award’ from the Foundation Fighting Blindness, enabling the company to advance preclinical development of its lead product, MM238. Recognizing Mireca’s pivotal role in targeting the cGMP pathway for treating…
Formosa & Cristália Partner for APP13007 Rights in Brazil
Formosa Pharmaceuticals announced a strategic licensing agreement with Cristália Produtos Químicos Farmacêuticos to secure exclusive commercialization rights for APP13007 (clobetasol propionate ophthalmic nanosuspension, 0.05%) in Brazil. APP13007 is designed for the treatment of inflammation and pain following ocular surgery and…
FDA Approves Modified Axpaxli Trial by Ocular Therapeutix
Ocular Therapeutix announced that the FDA has granted approval for a modification to the special protocol assessment (SPA) agreement for the pivotal phase 3 SOL clinical trial of Axpaxli (axitinib intravitreal implant, also known as OTX-TKI). This modification marks a…
Hearing Loss is Rare in Tepezza Treatment for TED
A recent study, led by Dr. Raymond Douglas, MD, PhD, revealed that long-term hearing loss is a rare occurrence in individuals with normal audiometry at baseline following treatment with Tepezza [teprotumumab]. Published in the current issue of the prestigious journal…
Sandoz Acquires Coherus’ Ophthalmology Assets for $170M
In a strategic move aimed at strengthening its focus on oncology and alleviating debt, Coherus BioSciences has entered into a definitive agreement to divest its Cimerli (ranibizumab-eqrn) ophthalmology franchise to Sandoz for a total consideration of $170 million in cash,…
FDA Approval and Funding for ONS-5010
In a significant stride towards advancing its clinical development program for ONS-5010, Outlook Therapeutics has received written agreement from the FDA under a special protocol assessment (SPA) for the NORSE EIGHT clinical trial protocol. This trial aims to evaluate the…
FTC Clears Amgen’s Acquisition of Horizon Therapeutics
Amgen is set to proceed with its acquisition of Horizon Therapeutics after reaching an agreement with the Federal Trade Commission (FTC). This agreement clears the way for Amgen to complete its acquisition of Horizon Therapeutics, a deal valued at $27.8…
Allotex Receives Funding for Allogeneic Presbyopia Inlays
Allotex and SpA have announced the successful completion of the first close of their $30 million Series B financing. The funds raised will be utilized to further develop their technology aimed at treating refractive errors. The decision to invest in…